Loading...
Infliximab is effective for short- and long-term treatment of Crohn disease. To evaluate the safety of infliximab, researchers retrospectively reviewed medical records of 500 patients who were treated with infliximab at Mayo Clinic in Rochester, Minnesota, from 1998 through 2002; 49% received induction therapy only, 32% received induction therapy followed by on-demand maintenance therapy, 15% received induction therapy followed by scheduled maintenance, and 4% received induction therapy followed by scheduled maintenance requiring increased dosing or shortened intervals. Median follow-up was 17 months, and the median number of infusions was 3.
Thirty patients (6%) had serious adverse events that were possibly related to infliximab use. Infect…